Drug Profile
Research programme: antigen inserted alpha virus like particle vaccines - VLP Therapeutics
Alternative Names: Dengue VLP vaccine; iα-VLP - VLP TherapeuticsLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator VLP Therapeutics
- Developer Georgetown University; Institute of Tropical Medicine, Nagasaki University; VLP Therapeutics
- Class Cancer vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Dengue; Infections
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Dengue(Prevention) in Japan (Parenteral)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Dengue(Prevention) in USA (Parenteral)
- 28 Apr 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)